Stay updated on AstraZeneca PLC ADR Press Releases

Sign up to get notified when there's something new on the AstraZeneca PLC ADR Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the AstraZeneca PLC ADR Press Releases page

  1. Check
    3 days ago
    Change Detected
    Summary
    Enhertu has received Priority Review in the US for specific breast cancer patients, and Tagrisso has been approved for unresectable, Stage III EGFR-mutated lung cancer.
    Difference
    74%
    Check dated 2024-10-03T04:25:52.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    Fasenra has been recommended for EU approval for eosinophilic granulomatosis with polyangiitis, while FluMist has received approval for self-administration in the US, marking significant advancements in treatment options.
    Difference
    71%
    Check dated 2024-09-25T22:04:25.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    Recent updates highlight significant advancements in cancer treatments, including the approval of Fasenra for eosinophilic granulomatosis and Imfinzi for non-small cell lung cancer, alongside promising trial results for various therapies demonstrating improved survival rates.
    Difference
    100%
    Check dated 2024-09-18T16:22:42.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The website now indicates 'No results found for your search', and several significant updates regarding drug approvals and clinical trial results have been removed, including approvals for Imfinzi and Enhertu.
    Difference
    47%
    Check dated 2024-09-11T06:54:13.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    AstraZeneca is enhancing its commitment to cancer care standards at upcoming conferences, while the recent approval of Tagrisso with chemotherapy for advanced lung cancer has been removed from the site.
    Difference
    10%
    Check dated 2024-09-04T02:49:55.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    Recent approvals include Fasenra for severe eosinophilic asthma in China and Imfinzi for resectable non-small cell lung cancer in the US, while notable deletions include the acceptance of Sipavibart's EMA submission for COVID-19 prevention.
    Difference
    67%
    Check dated 2024-08-20T22:58:08.000Z thumbnail image

Stay in the know with updates to AstraZeneca PLC ADR Press Releases

Enter your email address, and we'll notify you when there's something new on the AstraZeneca PLC ADR Press Releases page.